University Hospitals Seidman Cancer Center hosts first international pre-launch event for Siemens Healthineers new Accela

With fast radiotherapy treatment delivery and planning, Accela makes complex treatment more practical and scalable

• NeoArc (Dynamic Modulated Arc Therapy DMAT) is a breakthrough technique combining speed and precision
• NeoArc makes single breath-hold stereotactic treatment possible and enables multi-site stereotactic body radiation therapy (SBRT) treatment in as little as 60 seconds
• With fast treatment delivery and planning, Accela makes complex treatment more practical and scalable for cancer centers

CLEVELAND- University Hospitals Seidman Cancer Center hosted a contingent of international journalists, along with Siemens Healthineers, for the first pre- launch event for the highly anticipated Accela. The technology is the first radiotherapy solution engineered around NeoArc, combining speed and precision for a broad range of cases while improving the scalability of complex treatments and reducing the time patients spend in radiotherapy treatment.

Reporters from across Europe and South America traveled to UH Seidman Cancer Center for a tour of the new Accela technology, and one-on-one conversations with leading experts. UH Seidman Cancer Center is one of only a few healthcare institutions in the world with the new technology. The Accela solution allows for Stereotactic Body Radiation Therapy (SBRT) in a single breath-hold in as little as 60 seconds, shortening patient time on the treatment table.

"University Hospitals was the first site globally to enroll a patient in the SPEED clinical trial on Accela, providing eligible patients the opportunity to participate in research evaluating and co-developing the investigational technology." said Daniel Spratt, MD, Chair, Department of Radiation Oncology, UH Cleveland Medical Center, and the Vincent K. Smith Chair in Radiation Oncology, UH Seidman Cancer Center.

The planning software leverages AI and advanced algorithms allow clinicians to balance the optimization of treatment plan quality and delivery speed. In addition, Accela brings unmatched linac functionality, with a large HyperSight cone-beam CT imaging panel, a newly designed multi-leaf collimator, high-speed gantry rotation at 2.5 RPM, dose rates up to 40 Gy/min, and a new eight-megavolt flattening filter-free energy setting.

"In a prospective trial conducted at University Hospitals Cleveland Medical Center, participants received mock radiation therapy on Varian's Accela system. We found that Accela and its NeoArc (DMAT) delivery reduced radiation therapy delivery time for abdominal SBRT by 87%. While additional research may be needed, these early trial results contribute to a growing understanding of how treatment timelines may be optimized to improve patient experience, convenience, and comfort during cancer care." said Lauren Henke, MD, MSCI, Director of the Gastrointestinal Radiation Oncology service at UH Seidman Cancer Center.

For healthcare systems facing a rising cancer burden, growing treatment complexity, and staffing constraints, Accela expands radiotherapy treatment options, enables fast, more precise workflows and an improved experience for patients and clinicians.

"With current technologies, radiotherapy targeting metastatic disease takes 30-60 minutes per site for treatment. When you multiple that by 10-sites, it is really challenging for a patient to spend that much time getting treatment per day, and hard for clinics to keep up with demand. Preliminary data suggests that the Accela system is a disruptive technology that has the potential to address this growing clinical problem." said Henke. The development of Accela and NeoArc was informed through years of collaboration by Siemens Healthineers and an advisory group of leading cancer-research institutions in the United States and globally including UH Seidman Cancer Center.

^{The Accela 510(k) pending. Not available for sale in any market and no guarantee of commercialization or feature availability. radiotherapy solution is engineered around NeoArc dynamic modulated arc therapy (DMAT),2}